Project Grant R43AR084989
Award Date
9/20/24
Completion Date
8/31/25
Dollars Obligated
$299K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98121, USA
Similar Awards
This federal Project Grant award, totaling $317,476.00, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award will support research at the University of Alabama at Birmingham (UAB) to investigate the molecular genetic causes of gout flares. The project aims to conduct differential gene expression analysis of myeloid cell subsets in peripheral blood and...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Vanderbilt University a $393,412 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop engineered cells as agents for treating osteoarthritis. The project aims to leverage advanced cell design platforms to create synthetic receptor-controlled, joint-resident cells that can detect cartilage degeneration and then upregulate the expression of transgenes to promote...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado, operating as the University of Colorado, with a period of performance from July 4, 2024 to August 31, 2027. The funding will support the development of granular hydrogels for the controlled delivery of immunomodulatory and angiogenic extracellular vesicles to enhance...
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Cyrus Biotechnology, Inc., a minority-owned small disadvantaged business located in Seattle, WA. The funding supports research to develop an immunoglobulin G (IgG) protease enzyme for treating immune thrombocytopenia (ITP) and other IgG-mediated autoimmune diseases. Specifically, the research aims to...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...
This Project Grant award, valued at $570,878.00, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund research to define the efficacy of pharmacological activation of the G-protein coupled receptor GPR68 in modulating the dynamics of myofibroblasts during fibrotic tendon healing. The goal is to identify therapeutic approaches to enhance the...
This federal Project Grant award of $456,808.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) is supporting the development of advanced mass spectrometry imaging (MSI) technologies to spatially visualize proteins and glycans in musculoskeletal tissues. The primary awardee, the Buck Institute for Research on Aging, is collaborating with researchers at the University of...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) worth $735,372 to Brigham & Women's Hospital Inc. on May 15, 2025. The project, titled "T Cell Expression of Inflammatory Chemokine Receptors," aims to identify transcription factors and cytokines that regulate the expression of chemokine receptors, such as CCR2, CCR5, and CXCR6, on T cells in inflamed...
This federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop a novel joint-targeted antibody therapy for the treatment of rheumatoid arthritis (RA). The award, totaling $402,086, will support the research team's efforts to synthesize new collagen hybridizing peptide (CHP) structures with high affinity to denatured collagen, and to...